134 related articles for article (PubMed ID: 10395117)
1. Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study.
Dulaney Lopez AM; Rodriguez JC; Lopez-Samblas AM; Estes KS
Int J Clin Pharmacol Ther; 1999 Jun; 37(6):269-74. PubMed ID: 10395117
[TBL] [Abstract][Full Text] [Related]
2. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data.
Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P
Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507
[TBL] [Abstract][Full Text] [Related]
3. Five cephalosporins: pharmacokinetics and their relation to antibacterial potency.
Sohn C; Pitkin D; Grappel S; Zajac I; Actor P; Alexander F; Lentnek A; Wikler M; Stote R; Dubb J
Clin Ther; 1984; 6(4):560-70. PubMed ID: 6467282
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
6. Effect of frequency of administration on therapeutic efficacy of cefotaxime.
Parker RH
Clin Ther; 1984; 6(4):488-99. PubMed ID: 6088045
[TBL] [Abstract][Full Text] [Related]
7. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules.
Snoeck E; Jacqmin P; Sargentini-Maier ML; Stockis A
Epilepsy Res; 2007 Sep; 76(2-3):140-7. PubMed ID: 17851036
[TBL] [Abstract][Full Text] [Related]
8. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
9. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
Buijk SE; Gyssens IC; Mouton JW; Metselaar HJ; Groenland TH; Verbrugh HA; Bruining HA
J Antimicrob Chemother; 2004 Jul; 54(1):199-205. PubMed ID: 15175266
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
11. The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations.
Wilson WR; Bouza E; Lode H; Mouton Y
J Chemother; 1997 May; 9 Suppl 2():5-18. PubMed ID: 9248972
[TBL] [Abstract][Full Text] [Related]
12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic options for cefotaxime in the management of bacterial infections.
Raddatz JK; Ostergaard BE; Rotschafer JC
Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
[TBL] [Abstract][Full Text] [Related]
15. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics.
Nix DE; Schentag JJ
Diagn Microbiol Infect Dis; 1995; 22(1-2):71-6. PubMed ID: 7587053
[TBL] [Abstract][Full Text] [Related]
16. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
Conte JE; Golden JA; Kelley MG; Zurlinden E
Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
[TBL] [Abstract][Full Text] [Related]
17. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.
Krishna R; Krishnaswami S; Kittner B; Sankoh AJ; Jensen BK
Biopharm Drug Dispos; 2004 Dec; 25(9):373-87. PubMed ID: 15517550
[TBL] [Abstract][Full Text] [Related]
18. [Availability of cefotaxime. Pharmacokinetic studies on the distribution in central and various peripheral compartments (author's transl)].
Wittmann DH; Schassan HH; Welter J; Seidel H
MMW Munch Med Wochenschr; 1980 Apr; 122(17):637-41. PubMed ID: 6248774
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.
Béranger A; Oualha M; Urien S; Genuini M; Renolleau S; Aboura R; Hirt D; Heilbronner C; Toubiana J; Tréluyer JM; Benaboud S
Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
